

A New Oxidovanadium(IV) Complex of Oxodiacetic Acid and dppz: Spectroscopic and DFT Study. Antitumor Action on MG-63 Human Osteosarcoma Cell Line

Ignacio E. León · Beatriz S. Parajón-Costa ·
Carlos A. Franca · Susana B. Etcheverry ·
Enrique J. Baran

Received: 10 November 2014 / Accepted: 10 December 2014 / Published online: 23 December 2014
© Springer Science+Business Media New York 2014

Abstract The oxidovanadium(IV) complex of oxodiacetic acid (H_2ODA) and dppz (dipyrido[3,2-a:2',3'-c] phenazine) of stoichiometry $[\text{VO}(\text{ODA})(\text{dppz})]\cdot 3\text{H}_2\text{O}$ could be synthesized for the first time by reaction between $[\text{VO}(\text{ODA})(\text{H}_2\text{O})_2]$ and dppz. It was characterized by infrared and electronic spectroscopies. Its optimized molecular structure was obtained by DFT calculations, as it was impossible to grow single crystals adequate for crystallographic studies. The antitumor action of the complex on MG-63 human osteosarcoma cell line was also investigated. It was found that it caused a concentration-related inhibitory effect in the concentration range between 5 and 25 μM and diminished the cell viability ca. 45 % in the range from 25 to 100 μM , without dose/response effects in this range. These biological effects are, in general, similar to those previously reported for the related $[\text{VO}(\text{ODA})(\text{o phen})]\cdot 1.5\text{H}_2\text{O}$ complex.

Keywords Oxidovanadium(IV) · Oxodiacetic acid · dppz · DFT calculations · FTIR spectrum · Electronic spectrum · Human osteosarcoma cell line

Introduction

As part of a research project devoted to the characterization of vanadium compounds with potential pharmacological

applications, we have recently prepared and investigated the general physicochemical properties and the biological activity of some ternary oxidovanadium(IV) complexes containing the di-anion of oxodiacetic acid (H_2ODA) and H_2O , $[\text{VO}(\text{ODA})(\text{H}_2\text{O})_2]$ [1, 2] or the organic ligands *o*-phenanthroline (ophen), $[\text{VO}(\text{ODA})(\text{o phen})]\cdot 1.5\text{H}_2\text{O}$ [1, 3] and 2,2'-bipyridine (bipy), $[\text{VO}(\text{ODA})(\text{bipy})]\cdot \text{H}_2\text{O}$ [1, 4].

Oxodiacetate is a very interesting and versatile ligand, having five potential O-donor atoms in different orientations, allowing in this way the construction of networks of different dimensionalities [5]. In the case of the three above mentioned complexes, which present a distorted octahedral geometry, ODA occupies three coordination positions through two carboxylate O-atoms and the ethereal O-atom, generating the unprecedented tridentate OOO coordination [6–8].

Metallointercalators are small complex molecules that contain a planar aromatic heterocycle functionality which can insert and stack between the base pairs of double-helical DNA [9, 10]. In general, upon binding to DNA, metal complexes are stabilized through a series of weak interactions such as the π -stacking interactions of aromatic heterocyclic groups between the base pairs (intercalation), hydrogen bonding and van der Waals interactions of functional groups bound along the groove of the DNA helix [9].

Two of the best known and most investigated DNA intercalators are 2,2'-bipyridine and *o*-phenanthroline [9, 10]; but in our previous studies with the $[\text{VO}(\text{ODA})\text{L}]$ complexes, we have found that the presence of ophen increases the reactivity of $\text{VO}(\text{ODA})$ toward DNA, whereas the addition of bipy, shows a minor effect [1].

As an extension of these studies, we could now synthesize a similar complex of composition $[\text{VO}(\text{ODA})(\text{dppz})]\cdot 3\text{H}_2\text{O}$ -containing dppz (dppz = dipyrido[3,2-a:2',3'-c]phenazine), another well-known and characterized DNA-intercalator [9–16]. The heterocyclic π -system of this molecule combines the

I. E. León · S. B. Etcheverry
Cátedra de Bioquímica Patológica, Facultad de Ciencias Exactas,
Universidad Nacional de La Plata, 1900 La Plata, Argentina

I. E. León · B. S. Parajón-Costa · C. A. Franca · S. B. Etcheverry ·
E. J. Baran (✉)
Centro de Química Inorgánica (CEQUINOR/CONICET, UNLP),
Facultad de Ciencias Exactas, Universidad Nacional de La Plata,
C. Correo 962, 1900 La Plata, Argentina
e-mail: baran@quimica.unlp.edu.ar

chelating functions of α -diimines or “polypyridines”, such as the mentioned bipy and ophen ligands, with the electron transfer/proton transfer capacity of the 1,4-diazines [17]. As it was not possible to obtain single crystals of this new complex, adequate for crystallographic studies, its structural and geometric characteristics were derived from a theoretical DFT study. Besides, the characterization of the complex was complemented with the analysis of its FTIR and electronic absorption spectra. Finally, its antitumor activity was assayed on the MG-63 human osteosarcoma cell line in culture.

Materials and Methods

Materials

The monohydrate of *o*-phenanthroline and oxodiacetic acid was purchased from Aldrich, oxidovanadium(IV) acetylacetonate from Fluka, whereas $\text{VOSO}_4 \cdot 5\text{H}_2\text{O}$ and all the other reagents and solvents were from Merck. The dppz ligand was obtained in the following way: *o*-phenanthroline was first transformed into 5-nitro-*o*-phenanthroline by reaction with concentrated HNO_3 in the presence of oleum [18]. The nitro compound was subsequently reduced with SnCl_2 to 5-amino-*o*-phenanthroline [19], which is then reacted with a $\text{H}_2\text{SO}_4/\text{HNO}_3$ mixture to generate 5,6-quinone-*o*-phenanthroline [20]. Finally, ethanolic solutions of this quinone and *o*-phenylenediamine are mixed and shortly boiled, generating the dppz which after recrystallization from aqueous ethanol generates brown-orange needles of the hemihydrate, $\text{C}_{18}\text{H}_{10}\text{N}_4 \cdot 0.5\text{H}_2\text{O}$, (m.p. 250 °C) [20]. The precursor complex, $[\text{VO}(\text{ODA})(\text{H}_2\text{O})_2]$, was prepared by reaction of oxidovanadium(IV) acetylacetonate and oxodiacetic acid as reported earlier [2, 6].

Tissue culture materials were purchased from Corning (Princeton, NJ, USA), Dulbecco's Modified Eagles Medium (DMEM), TrypLETM from Gibco (Gaithersburg, MD, USA), and fetal bovine serum (FBS) from Internegocios SA (Argentina). All other chemicals, used in the biological assays, were from Sigma Chemical Co. (ST. Louis, MO). MG-63 cell line was purchased from ATCC (CRL1427TM).

Synthesis of the Complex

The new complex was obtained by slow addition of 0.145 g (0.5 mmol) of dppz·0.5H₂O to 15 mL of a methanolic solution containing 0.117 g (0.5 mmol) of the precursor complex, at room temperature, and under continuous stirring. Although a solid compound begins to precipitate practically immediately, agitation of the mixture was continued during one more hour. The obtained precipitate was collected by filtration, washed with cold methanol, and dried in air (yield ca. 0.25 g). The purity was confirmed by elemental chemical analysis (Calcd.

for $\text{C}_{22}\text{H}_{14}\text{N}_4\text{O}_6\text{V} \cdot 3\text{H}_2\text{O}$: C, 49.34; H, 3.73; N, 10.46; V, 9.53 %; found: C, 49.20; H, 3.80; N, 10.42; V, 9.47 %).

The complex is highly insoluble in all of the common solvents and, therefore, it was impossible to obtain single crystals adequate for a crystal structural analysis.

Spectroscopic Characterization

Infrared spectra in the spectral range between 4000 and 400 cm^{-1} were obtained with a Bruker EQUINOX 55 Fourier transform infrared spectroscopy (FTIR) instrument, using the KBr pellet technique. Electronic absorption spectra were measured on DMSO solutions of the complex, with a Shimadzu model UV-300 spectrophotometer, using 10-mm quartz cells.

Cell Culture and Incubations

MG-63 human osteosarcoma cells (CRL1427TM) were grown in DMEM containing 10 % FBS, 100 U/mL penicillin, and 100 $\mu\text{g}/\text{mL}$ streptomycin at 37 °C in 5 % CO_2 atmosphere. Cells were seeded in a 75- cm^2 flask, and when 70–80 % of confluence was reached, cells were subcultured using 1 mL of TrypLETM per 25 cm^2 flask. For experiments, cells were grown in multiwell plates. When cells reached the desired confluence, the monolayers were washed with DMEM and were incubated under different conditions according to the experiments.

MTT Assay

The MTT assay was performed according to T. Mosmann [21]. Briefly, cells were seeded in a 96-multiwell dish, allowed to attach for 24 h, and treated with different concentrations of complexes at 37 °C for 24 h. After that, the medium was changed, and the cells were incubated with 0.5 mg/mL MTT under normal culture conditions for 3 h. Cell viability was marked by the conversion of the tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium-bromide) to a colored formazan by mitochondrial dehydrogenases. Color development was measured spectrophotometrically in a Microplate Reader (7530, Cambridge Technology, Inc, USA) at 570 nm after cell lysis in DMSO (100 $\mu\text{L}/\text{well}$). Cell viability was plotted as the percentage of the control value.

Statistical Methods

At least three independent experiments were performed for each experimental condition. Results are expressed as percent basal and represent the mean \pm SEM. Statistical differences were analyzed using the ANOVA test.

Computational Details

The optimized geometry of [VO(ODA)dppz] complex was obtained using the M0L6 Truhlar's functionals [22] from the density functional theory as implemented in the Gaussian 09 package [23]. The basis set of triple zeta valence quality augmented with polarization functions was used for hydrogen, carbon, and vanadium atoms [24]. For oxygen and nitrogen atoms, the same basis plus diffuse functions [25] were used.

Vibrational analysis was carried out at the same level of theory to confirm that this structure is a minimum on the potential energy surfaces. Furthermore, the bands of the infrared spectrum were also calculated to compare them with the experimental data and to support the assignment of the observed vibrational modes.

The electronic transitions were calculated at the optimized ground-state geometry within the context of the TD-DFT theory using the functional M06L and the LanL2DZ basis set, which uses Dunning D95V basis set [26] on hydrogen, carbon, nitrogen, and oxygen atoms, and Los Alamos ECP plus DZ on vanadium atom [27]. UV-visible spectral calculations were carried out including solvent effects (DMSO) through the polarizable continuum model [28] as implemented in the Gaussian 09 package to produce a number of 20 singlet-to-singlet transitions.

Results and Discussion

Structural Characteristics of the Complex

The computer-optimized structure of the complex is shown in Fig. 1. The vanadium presents a distorted octahedral coordination and the oxodiacetate anion acts as a tridentate [OOO] chelating ligand. The equatorial plane is occupied by the carboxylate oxygen atoms (O2 and O2') of this ligand and the heterocyclic N-atoms (N1 and N2), whereas the axial

positions are conformed by the ethereal O-atom of oxodiacetate (O1) and the vanadyl V=O-oxygen (O5).

Selected bond distances and angles are shown in Table 1. The V=O distance is similar to those determined experimentally, by X-ray crystallography, in the cases of [VO(ODA)(ophen)]·1.5H₂O [7] and [VO(ODA)(bipy)]·H₂O [8], the V-O distance *trans* to this bond, is somewhat larger in the present case, whereas the other V-O and V-N bonds are comparable in all these cases.

IR-spectrum of [VO(ODA)(dppz)]·3H₂O

The FTIR spectrum of the complex in the most interesting spectral range, between 2000 and 400 cm⁻¹, is shown in Fig. 2. The spectrum was not only analyzed on the basis of the results of the theoretical calculations but also by comparison with the spectra of the free oxodiacetic acid [2] and dppz [29], as well as by information provided by well known standard reference texts [30, 31]. The proposed assignments are presented in Table 2 and are briefly commented as follows:

- The stretching vibrations of the water molecules (not shown in Fig. 2) generate a very strong and broad IR band centered at 3421 cm⁻¹, with two weak additional bands at its lower energy side, related to CH and CH₂ motions. The position of the strong OH band points to the participation of the water molecules in hydrogen bonds of medium strength [32, 33]. The corresponding deformational mode, $\delta(\text{H}_2\text{O})$, is surely overlapped by the strong 1657 cm⁻¹ band.
- The carboxylate groups of ODA show the typical spectroscopic behavior expected from a monodentate interaction of this ligand with the metallic center, i.e., the anti-symmetric stretching vibration presents a lower energy than those found for the $\nu(\text{C}=\text{O})$ vibration in the “free” acid (1734 cm⁻¹) [2], whereas the symmetric mode lies somewhat higher than the corresponding $\nu(\text{C}=\text{O})$ mode 1309 cm⁻¹ in the free acid) [2]. Besides, both

Fig. 1 Optimized geometry of the [VO(ODA)(dppz)] complex obtained by the DFT calculations





Table 1 Selected bond distances (Å) and angles (°) calculated for the [VO(ODA)(dppz)] complex

V-O5	1.584	C2-O1-C2'	116.8
V-O2=V-O2'	1.944	O1-C2-C1	113.0
V-O1	2.408	O1-C2'-C1'	113.0
V-N1=V-N2	2.146	N1-V-N2	75.8
		O5-V-N1	103.7
O5-V-O1	178.4	O5-V-N2	103.7
O5-V-O2	104.8	O2-V-N1	85.9
O5-V-O2'	104.8	O2-V-N2	149.0
O1-V-O2	74.1	O2'-V-N1	149.0
O1-V-O2'	74.1	O2'-V-N2	85.9
O2-V-O2'	98.1	O1-V-N1	77.5

carboxylate stretchings also show an energy difference (about 300 cm^{-1}), which is a characteristic for monodentate binding [34].

- The $\nu_{\text{as}}(\text{C-O-C})$ and $\nu_{\text{s}}(\text{C-O-C})$ motions of the ethereal moiety of ODA are slightly displaced to lower energies after interaction of its O-atom with the metal center. The corresponding deformational mode of this grouping could not be identified with certainty because, as shown by the theoretical calculations, it is strongly coupled with other motions.
- The characteristic $\nu(\text{V=O})$ breathing appears in the usually expected region [35] and practically at the same energy as found for [VO(ODA)(ophen)] $\cdot 1.5\text{H}_2\text{O}$ [3] and [VO(ODA)(bipy)] $\cdot \text{H}_2\text{O}$ [4] in agreement with the almost identical V=O bond lengths in the three compounds. We have also tentatively assigned one of the expected V-O metal-to-ligand vibrations at 430 cm^{-1} .
- IR bands of the dppz rings have not been assigned in detail, because the assignments in such a large molecule, involving simultaneous motions of many atoms, are

**Fig. 2** FT-infrared spectra of [VO(ODA)(dppz)] $\cdot 3\text{H}_2\text{O}$ in the spectral range between 2000 and 400 cm^{-1} **Table 2** Assignment of the FTIR spectrum of [VO(ODA)(dppz)] $\cdot 3\text{H}_2\text{O}$ (band positions in cm^{-1})

Band position	Assignment
3241 vs, br	$\nu(\text{OH})$
3086 w, 2932 w	$\nu(\text{CH})+\nu(\text{CH}_2)$
1681 sh	$\nu_{\text{ring}}+\delta(\text{CH})$
1657 vs	$\nu_{\text{as}}(\text{COO}^-)$
1580 sh	ν_{ring}
1498 m	$\delta(\text{CH}_2)$
1463 sh, 1449 sh	$\delta(\text{CH}_2)+\delta(\text{CH})+\nu_{\text{ring}}$
1418 m	$\delta(\text{CH}_2)+\nu_{\text{ring}}$
1359 s, 1340 w	$\nu_{\text{s}}(\text{COO}^-)+\delta(\text{CH})$
1316 m	$\delta(\text{CH})$
1289 sh	$\nu(\text{CN})+\tau(\text{CH}_2)$
1235 w, 1188 w	ν_{ring}
1136 s	$\nu_{\text{as}}(\text{C-O-C})+\nu_{\text{ring}}$
1078 s, 1071 sh	$\delta_{\text{ring}}+\delta(\text{CH})$
1051 m, 1040 sh	$\delta_{\text{ring}}+\delta(\text{CH})$
999 s	$\nu(\text{V=O})$
977 m, 922 s	ν_{ring}
822 m	$\nu_{\text{s}}(\text{C-O-C})+\gamma_{\text{ring}}$
778 m, 769 sh	$\delta(\text{CH})+\delta_{\text{ring}}$
732 s, 721 sh	$\gamma(\text{CH})+\gamma_{\text{ring}}+\rho(\text{CH}_2)$
656 vw, 636 vw	$\delta_{\text{ring}}+\delta(\text{CH})$
618 w	$\gamma_{\text{ring}}+\gamma(\text{CH})+\tau(\text{CH}_2)$
574 w, 563 w, 516 vw	$\gamma(\text{CH})+\tau(\text{CH}_2)$
452 m	$\delta(\text{C-O-C}) (?)$
430 m	$\nu(\text{V-O})+\gamma_{\text{ring}}$

vs very strong, s strong, m medium, w weak, vw very weak, br broad, sh shoulder


relatively complex [29]. Based on the previous studies, one can add to the data presented in Table 2 that ring modes observed at 1580, 1078/1071, and 1051/1040 cm^{-1} correspond to phenanthroline-based modes, whereas that located at 1418 cm^{-1} is a phenazine-based vibration [29].

- Certain vibrations are additionally complicated by superposition between ring modes and motions of part of the complex moiety. As an example, the 922- cm^{-1} ring mode involves also a O-V-O stretching, coupled with other ODA modes. Also, the last two observed vibrations (452 and 430 cm^{-1}) are partially affected by a complex deformation of the whole ODA ligand.

Electronic Absorption Spectrum

It was very difficult to obtain the electronic absorption spectrum of the complex due to its mentioned great insolubility in

Fig. 3 Calculated electronic spectrum of the [VO(ODA)(dppz)] complex



all of the common solvents. We have only obtained reproducible results with diluted DMSO solutions. In this case, we found only one absorption band located at 452 nm ($\epsilon=110$ L/mol cm).

The calculated electronic spectrum is shown in Fig. 3, and the electronic transitions are described in Table 3, including band positions, oscillator strengths, and proposed assignments (A and B indicate the electronic space of alpha and beta electrons, respectively).

The HOMO (A) is mainly constituted by the d_{xy} orbital of the vanadium atom. H (B) and H-1 (A) are constituted of a π bonding system localized over the dppz ring, H-2 (A) contains p orbitals of the O-atoms of ODA and C-C and C-H σ orbitals of the same ligand. The H-3 (A) and H-2 (B) involve nitrogen p and σ C-N orbitals from the N-atoms lying away from the metal center.

Table 3 Calculated electronic transitions for [VO(ODA)(dppz)]

Wavelength (nm)	Oscillator strength	Assignment
709.29	0.0002	HOMO (A) \rightarrow L+3 (A) (76 %)
682.73	0.0002	HOMO (A) \rightarrow L+1 (A) (20 %), HOMO (A) \rightarrow L+4 (A) (68 %)
505.62	0.0008	HOMO (A) \rightarrow L+6 (A) (13 %), HOMO (A) \rightarrow L+7 (A) (71 %)
396.48	0.0032	HOMO (A) \rightarrow LUMO (A) (15 %), HOMO (A) \rightarrow L+1 (A) (47 %), HOMO (A) \rightarrow L+8 (A) (14 %)
377.26	0.0032	H-3 (A) \rightarrow LUMO (A) (47 %), H-2 (B) \rightarrow LUMO (B) (47 %)
362.48	0.0005	HOMO (A) \rightarrow LUMO (A) (82 %)
343.84	0.0322	H-1 (A) \rightarrow LUMO (A) (48 %), HOMO (B) \rightarrow LUMO (B) (48 %)

The LUMO (A) and HOMO (B) consist both of a π^* system localized on the dppz moiety, while L+1 (A) is mainly the d_{yz} orbital of vanadium plus a π system on the ring fragment closer to the metal center. L+3 (A) is the d_{xz} orbital of the vanadium atom, and L-4 (A) contains a certain contribution of the metal d_{yz} orbital. L+6 (A) and L+7 (A) are both constituted by the $d_{x^2-y^2}$ vanadium orbital, whereas L+8 (A) is the d_z^2 metal orbital.

As it can be seen from the results analyzed in Table 3, most of the calculated absorptions are of complex origin involving various transitions.

The measured 452-nm absorption may be eventually related to the calculated 396.48 nm band. Besides, bands calculated at 709.29/682.73 nm and at 505.62 nm eventually correspond to the 820 and 580 nm transitions measured in the case




Fig. 4 Evaluation of the mitochondrial succinate dehydrogenase activity by the MTT assay in MG-63 cells in culture. Osteosarcoma cells were incubated with different doses (25–100 μ M) of the complex for 24 h at 37 $^{\circ}$ C. After incubation, cell viability was determined by the MTT assay. Results are expressed as % basal and represent the mean \pm SEM, $n=18$. Asterisk shows significant differences vs. control ($p < 0.01$)

of $[\text{VO}(\text{ODA})(\text{o phen})]\cdot 1.5\text{H}_2\text{O}$ [7], which are characteristics for these type of complexes, but which were not found in the present case due to the commented scarce solubility of the complex.

Effects of $[\text{VO}(\text{ODA})(\text{dppz})]\cdot 3\text{H}_2\text{O}$ on Human Osteosarcoma Cell Viability

Multiple biological effects of vanadium have been involved in its inhibitory actions on many tumor cells [36]. Considering the high accumulation of vanadium in bone [37–39], it is of high interest to determine the effect of the new vanadium complex at the hard tissue level. Therefore, and as part of our mentioned project devoted to the characterization of vanadium complexes with antitumor properties, we have tested the effect of this new complex on human osteosarcoma cells in culture. Its action on the cellular viability was determined on MG-63 human osteosarcoma cell line, which is considered as a good model for bone tissue cancer [40].

Figure 4 shows the effects of the complex $[\text{VO}(\text{ODA})(\text{dppz})]\cdot 3\text{H}_2\text{O}$ on the mitochondria metabolism of MG-63 osteosarcoma cells. As it can be seen, the complex caused a concentration-related inhibition from 5 to 25 μM with statistically significant differences versus basal condition ($p < 0.01$). Moreover, the compound diminished the cell viability ca. 45 % in the range from 25 to 100 μM ($p < 0.01$). Nevertheless, it did not exhibit a dose response effect in this range of concentrations. Comparing the effects of the new complex with those of the previously reported complex of the oxidovanadium(IV) cation with oxodiacetate and *o*-phenanthroline, $[\text{VO}(\text{ODA})(\text{o phen})]\cdot 1.5\text{H}_2\text{O}$ [3], it can be seen that the biological behavior of both vanadium(IV) complexes on MG-63 cells is similar [1].

On the contrary, in the evaluation of the related VO^{2+} complex with bipyridine $[\text{VO}(\text{ODA})(\text{bipy})]\cdot \text{H}_2\text{O}$ [4] and with $[\text{VO}(\text{ODA})(\text{H}_2\text{O})_2]$ [2], considered as the precursor of this series of related compounds, the damage was observed only in the higher concentration range (50–100 μM) [1]. These results reinforce again the hypothesis of the importance of using strong intercalating ligands (o phen and dppz) in the generation of new compounds with potential antitumor properties.

Acknowledgments This research was supported by the Universidad Nacional de La Plata, the Agencia Nacional de Promoción Científica y Tecnológica-ANPCyT (PICT 2218), and the Consejo Nacional de Investigaciones Científicas y Técnicas-CONICET (PIP 1125 and PIP 5078). The authors are indebted to Dr. J. Zinczuk, Instituto de Química de Rosario (IQUIR/CONICET,UNR), Rosario, Argentina, for the synthesis of dppz. IEL is a fellow from CONICET and BSPC, and SBE are members of the Research Career from CONICET. CAF acknowledges the Universidad Nacional de Catamarca for computing time.

References

- León IE, Butenko N, Di Virgilio AL, Muglia CI, Baran EJ, Cavaco I, Etcheverry SB (2014) Vanadium and cancer treatment: antitumoral mechanisms of three oxidovanadium(IV) complexes on a human osteosarcoma line. *J Inorg Biochem* 134:106–117
- Rivadeneira J, Barrio DA, Etcheverry SB, Baran EJ (2007) Spectroscopic characterization of a VO^{2+} complex of oxodiacetic acid and its bioactivity on osteoblast-like cells in culture. *Biol Trace Elem Res* 118:159–166
- Leon IE, Etcheverry SB, Parajón-Costa BS, Baran EJ (2012) Spectroscopic characterization of an oxovanadium(IV) complex of oxodiacetic acid and *o*-phenanthroline. Bioactivity on osteoblast-like cells in culture. *Biol Trace Elem Res* 147:403–407
- Leon IE, Etcheverry SB, Parajón-Costa BS, Baran EJ (2013) Spectroscopic characterization of an oxovanadium(IV) complex of oxodiacetic acid and 2,2'-bipyridine. Bioactivity on osteoblast-like cells in culture. *J Mex Chem Soc* 57:175–179
- Grirrane A, Pastor A, Ienco A, Mealli C, Galindo A (2002) Synthesis and molecular structure of oxodiacetate complexes of nickel(II) and cobalt(II). Theoretical analysis of the planar and non-planar conformation of oxodiacetate ligand and oxodiacetic acid. *Dalton Transact* 2002:3771–3777
- del Rio D, Galindo A, Tejedo J, Bedoya FJ, Ienco A, Mealli C (2000) Synthesis, molecular structure and properties of oxovanadium(IV) complexes containing the oxodiacetate ligand. *Inorg Chem Comm* 3: 32–34
- Álvarez L, Grirrane A, Moyano R, Álvarez E, Pastor A, Galindo A (2010) Comparison of the coordination capabilities of thiodiacetate and oxodiacetate ligands through the X-ray characterization and DFT studies of $[\text{VO}(\text{dta})(\text{phen})]\cdot 4\text{H}_2\text{O}$ and $[\text{VO}(\text{oda})(\text{phen})]\cdot 1.5\text{H}_2\text{O}$. *Polyhedron* 29:3028–3035
- del Rio D, Galindo A, Vicente R, Mealli C, Ienco A, Mais D (2003) Synthesis, molecular structure and properties of oxo-vanadium(IV) complexes containing the oxodiacetate ligand. *Dalton Transact* 2003: 1813–1820
- Erkkila KE, Odom DT, Barton JK (1999) Recognition and reaction of metallointercalators with DNA. *Chem Rev* 99:2777–2795
- Liu HK, Sadler PJ (2011) Metal complexes as DNA intercalators. *Acc Chem Res* 44:349–359
- Chen W, Turro C, Friedman LA, Barton JK, Turro NJ (1997) Resonance Raman investigation of $\text{Ru}(\text{phen})_2(\text{dppz})^{2+}$ and related complexes in water and in the presence of DNA. *J Phys Chem B* 101: 6995–7000
- Navarro M, Hernández C, Colmenares I, Hernández P, Fernández M, Sierralta A, Marchán E (2007) Synthesis and characterization of $[\text{Au}(\text{dppz})_2]\text{Cl}_3$. DNA interaction studies and biological activity against *Leishmania (L) mexicana*. *J Inorg Biochem* 101:111–116
- Benítez J, Guggeri L, Tomaz I, Arrambide G, Navarro M, Costa Pessoa J, Garat B, Gambino D (2009) Design of vanadium mixed-ligand complexes as potential anti-protozoa agents. *J Inorg Biochem* 103:609–616
- Benítez J, Guggeri L, Tomaz I, Costa Pessoa J, Moreno V, Lorenzo J, Avilés FX, Garat B, Gambino D (2009) A novel vanadyl complex with a polypyridyl DNA intercalator as ligand: a potential anti-protozoa and anti-tumor agent. *J Inorg Biochem* 103:1386–1394
- Sánchez-Delgado RA, Anzellotti A, Suárez L (2004) Metal complexes as chemotherapeutic agents against tropical diseases: malaria, trypanosomiasis and leishmaniasis. In: Sigel A, Sigel H (eds) *Metal ions in biological systems*, vol. 41: Metal ions and their complexes in medication. Marcel Dekker, New York, pp 379–419
- Navarro M, Gabbiani C, Messori L, Gambino D (2010) Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives. *Drug Disc Today* 15:1070–1078

17. Klein A, Scheiring T, Kaim W (1999) Molecular and crystal structure of an organoplatinum(II) complex with dipyrido[3,2-2',3'-c]phenazine (dppz). *Z Anorg Allg Chem* 625:1177–1180
18. Smith GF, Cagle FW (1947) The improved synthesis of 5-nitro-1,10-phenanthroline. *J Org Chem* 12:781–784
19. Koft E, Case FH (1962) Substituted 1,10-phenanthrolines. XII. Benzo and pyrido derivatives. *J Org Chem* 27:865–868
20. Dickeson JE, Summers LA (1970) Derivatives of 1,10-phenanthroline-5-6-quinone. *Aust J Chem* 23:1023–1027
21. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods* 65:55–63
22. Zhao Y, Truhlar DG (2008) The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: two new functionals and systematic testing of four M06-class functionals and 12 other functionals. *Theor Chem Acc* 120:215–241
23. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Mennucci B, Petersson GA, Nakatsuji H, Caricato M, Li X, Hratchian HP, Izmaylov AF, Bloino J, Zheng G, Sonnenberg JL, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Vreven T, Montgomery JJA, Peralta JE, Ogliaro F, Bearpark M, Heyd JJ, Brothers E, Kudin KN, Staroverov VN, Keith T, Kobayashi R, Normand J, Raghavachari K, Rendell A, Burant JC, Iyengar SS, Tomasi J, Cossi M, Rega N, Millam JM, Klene M, Knox JE, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Martin RL, Morokuma K, Zakrzewski VG, Voth GA, Salvador P, Dannenberg JJ, Dapprich S, Daniels AD, Farkas O, Foresman JB, Ortiz JV, Cioslowski J, Fox DJ (2010) Gaussian-09. Gaussian Inc., Wallingford
24. Weigend F, Ahlrichs R (2005) Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence qualify for H to Rn: design and assessment of accuracy. *Phys Chem Chem Phys* 7:3297–3305
25. Rappoport D, Furche F (2010) Property-optimized Gaussian basis sets for molecular response calculation. *J Chem Phys* 133:134105
26. Dunning TH Jr, Hay PJ (1976) In: Schaefer HF III (ed) *Modern theoretical chemistry*, vol 3. Plenum, New York, pp 1–28
27. Hay PJ, Wadt WR (1985) Ab initio effective core potentials for molecular calculations. Potentials for the transition metal atoms Sc to Hg. *J Chem Phys* 82:270
28. Barone V, Cossi M (1998) Quantum calculation of molecular energies and energy gradients in solution by a conductor solvent model. *J Phys Chem A* 102:1995–2001
29. Matthewson BJ, Flood A, Polson MIJ, Armstrong C, Phillips DL, Gordon KC (2002) Vibrational spectra of dipyrido[3,2-a:2',3'-c]phenazine and its radical anion analyzed by ab initio calculations and deuteration studies. *Bull Chem Soc Jpn* 75:933–942
30. Lin-Vien D, Colthup NB, Fateley WG, Grasselli JG (1991) *The handbook of infrared and Raman characteristic frequencies of organic molecules*. Academic, Boston
31. Smith B (1999) *Infrared spectral interpretation*. CRC, Boca Raton
32. Siebert H (1966) *Anwendungen der Schwingungsspektroskopie in der Anorganischen Chemie*. Springer, Berlin
33. Libowitzky E (1999) Correlation of O-H stretching frequencies and O-H...O hydrogen bond lengths in minerals. *Monatsh Chem* 130:1047–1059
34. Nakamoto K (1997) *Infrared and Raman spectra of inorganic and coordination compounds*, 5th edn. Wiley, New York
35. Baran EJ (2001) Review: spectroscopic studies of oxovanadium coordination compounds. *J Coord Chem* 54:215–238
36. Bishayee A, Wagharay A, Patel MA, Chatterjee M (2010) Vanadium in the detection, prevention and treatment of cancer: the in vivo evidence. *Cancer Lett* 294:1–12
37. Rehder D (2008) *Bioinorganic vanadium chemistry*. Wiley, Chichester
38. Baran EJ (2008) Vanadium detoxification: chemical and biochemical aspects. *Chem Biodivers* 5:1475–1484
39. Rehder D (2012) The potentiality of vanadium in medicinal applications. *Future Med Chem* 4:1823–1837
40. Mohsen AB, Machado I, Cai Y, Schaefer KL, Serra M, Hogendoorn PC, Llombart-Bosch A, Cleton-Jansen AM (2011) Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. *Lab Invest* 91:1195–1205